# ScoreItem: Outras doenças renais

**ID:** `019bf31d-2ef0-7a7d-815c-a56b3e3735c9`
**FullName:** Outras doenças renais (Histórico de doenças - Doenças crônicas (Questionar ativamente as doenças crônicas mais comuns, perguntar sobre duração, grau de controle e tratamentos utilizados no passado e atualmente))

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 1 artigos
- Avg Similarity: 0.586

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7a7d-815c-a56b3e3735c9`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7a7d-815c-a56b3e3735c9",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Outras doenças renais (Histórico de doenças - Doenças crônicas (Questionar ativamente as doenças crônicas mais comuns, perguntar sobre duração, grau de controle e tratamentos utilizados no passado e atualmente))

**30 chunks de 1 artigos (avg similarity: 0.586)**

### Chunk 1/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.633

RifCKDisdeemedlikelyduetopresenceofotherclinicalindicators.1.1.4Evaluationofcause
PracticePoint1.1.4.1:EstablishthecauseofCKDusingclinicalcontext,personalandfamilyhistory,socialandenvi-ronmentalfactors,medications,physicalexamination,laboratorymeasures,imaging,andgeneticandpathologicdiagnosis(Figure8).
www.kidney-international.orgsummaryofrecommendationstatementsandpracticepointsKidneyInternational(2024)105(Suppl4S),S117–S314S149

PracticePoint1.1.4.2:Useteststoestablishacausebasedonresourcesavailable(Table622,98-100).Recommendation1.1.4.1:Wesuggestperformingakidneybiopsyasanacceptable,safe,diagnostictesttoevaluatecauseandguidetreatmentdecisionswhenclinicallyappropriate(2D).1.2EvaluationofGFR1.2.1OtherfunctionsofkidneysbesidesGFR
PracticePoint1.2.1.1:Usetheterm“GFR”whenreferringtothespecickidneyfunctionofglomerularltration.Usethemoregeneralterm“kidneyfunction(s)”whendealingwiththetotalityoffunctionsofthekidney.

---

### Chunk 2/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.623

k forrecurrence afterkidney transplantationConditions for whichgenetic testing isrelevant for reproductivecounselingExamples:• GLA (Fabry)• AGXT (primaryhyperoxaluria (PH))• CoQ10 genes (SRNS)• CTNS (cystinosis)• Tubulopathies(Na+, K+ etc.)Conditions amenable to nonspecific renoprotective strategiesExample:• COL4A3/4/5 (Alport)and RAAS blockadeExample:
• Glomerular diseasedue to mutations inAlport genes(COL4A3/4/5)Examples:• (CFH/CFI/C3...): aHUS• (AGXT, GRHPR, HOGA): primary hyperoxaluria (PH)
• Adenine phosphoribo-  syltransferase deficiency (APRT)Conditions amenable to specific screening for extrarenal manifestationsExamples:• HNF1B: diabetes• PKD1/PKD2(ADPKD): intracranialaneurysms • FLCN: renal cellcarcinoma, etc.Example:
• Prenatal/preimplantationdiagnosis
Figure9|Actionablegenesinkidneydisease.Actionabilityreferstothepotentialforgeneticrestresultstoleadtospecicclinicalactionsfrompreventionortreatmentofacondition,supportedbyrecommendationsbasedonevide

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.613

aticreviews,asavailable.DetailsofthePICOSforthesequestionsarealsoprovidedinTable44.Literaturesearchesandarticleselection.SearchesforRCTswereconductedonPubMed,Embase,andtheCochrane
CentralRegisterofControlledTrials(CENTRAL),and
searchesfordiagnosis/prognosisstudieswereconductedon
PubMed,Embase,andCINAHL.Fortopicswithavailable
existingreviews,thereviewwasusedandanupdatedsearchwasconducted.ThesearchstrategiesareprovidedinAppendixA:SupplementaryTableS1.Toimproveefciencyandaccuracyinthetitle/abstractscreeningprocessandtomanagetheprocess,searchresults
wereuploadedtoaweb-basedscreeningtool,PICOPortal
(www.picoportal.net).PICOPortalusesmachinelearningtosortandpresentthosecitationsmostlikelytobepromotedto
full-textscreeningrst.Thetitlesandabstractsresultingfrom
methodsforguidelinedevelopmentwww.kidney-international.orgS274KidneyInternational(2024)105(Suppl4S),S117–S314

Table44|ClinicalquestionsandsystematicreviewtopicsinPICOSformatChapter1Evaluationofchronickidneydisease(CKD)Clinicalquesti

---

### Chunk 4/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.601

e-basedequations.TransplInt.2012;25:527–536.162.JanusN,Launay-VacherV,ByloosE,etal.CancerandrenalinsufciencyresultsoftheBIRMAstudy.BrJCancer.2010;103:1815–1821.163.Launay-VacherV,JanusN,DerayG.Renalinsufciencyandcancertreatments.ESMOOpen.2016;1:e000091.164.NaSY,SungJY,ChangJH,etal.Chronickidneydiseaseincancerpatients:anindependentpredictorofcancer-specicmortality.AmJNephrol.2011;33:121–130.165.RosnerMH,JhaveriKD,McMahonBA,etal.Onconephrology:the
intersectionsbetweenthekidneyandcancer.CACancerJClin.2021;71:47–77.166.SoveriI,BergUB,BjorkJ,etal.MeasuringGFR:asystematicreview.AmJKidneyDis.2014;64:411–424.167.WhiteCA,AkbariA,AllenC,etal.Simultaneousglomerularltrationratedeterminationusinginulin,iohexol,and99mTc-DTPAdemonstratestheneedforcustomizedmeasurementprotocols.KidneyInt.2021;99:957–966.168.XieP,HuangJM,LiuXM,etal.(99m)Tc-DTPArenaldynamicimaging
methodmaybeunsuitabletobeusedasthereferencemethodin
investigatingthevalidityofCDK-EPIequationfordetermining
glomerularltrati

---

### Chunk 5/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.598

ersbladder,nuclearmedicinestudies,MRIAssesskidneystructure(i.e.,kidneyshape,size,symmetry,andevidenceofobstruction)forcysticdiseaseandreuxdisease.Evolvingroleofadditionaltechnologies(e.g.,3Dultrasound)KidneybiopsyUltrasound-guidedpercutaneousUsuallyexaminedbylightmicroscopy,immunouorescence,andelectronmicroscopy,and,insomesituations,mayincludemoleculardiagnostics
Usedforexactdiagnosis,planningtreatment,assessingactivityand
chronicityofdisease,andlikelihoodoftreatmentresponse;mayalsobe
usedtoassessgeneticdiseaseLaboratorytests:
serologic,urine
testsChemistryincludingacid-baseandelectrolytes,
serologictestssuchasanti-PLA2R,ANCA,anti-GBM
antibodies
Serum-freelightchains,serum,andurineprotein
electrophoresis/immunoxationUrinalysisandurinesedimentexaminationRefertoKDIGO2021ClinicalPracticeGuidelinefortheManagementofGlomerularDiseases22Increasingrecognitionoftheroleoflightchainsinkidneydiseaseevenin
theabsenceofmultiplemyeloma(monoclonalgammopathyofrenal
signicance[MGRS])98Presenceofpers

---

### Chunk 6/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.596

ta-analysis.ClinJAmSocNephrol.2022;17:1305–1315.193.vanEeghenSA,WiepjesCM,T’SjoenG,etal.CystatinC-basedeGFRchangesduringgender-afrminghormonetherapyintransgenderindividuals.ClinJAmSocNephrol.2023;18:1545–1554.194.PierreC,MarzinkeM,AhmedSB,etal.AACC/NKFguidancedocumenton
improvingequityinchronickidneydiseasecare.JApplLabMed.2023;8:789–816.195.NgDK,FurthSL,WaradyBA,etal.Self-reportedrace,serumcreatinine,
cystatinC,andGFRinchildrenandyoungadultswithpediatrickidney
referenceswww.kidney-international.orgS298KidneyInternational(2024)105(Suppl4S),S117–S314

diseases:areportfromtheChronicKidneyDiseaseinChildren(CKiD)study.AmJKidneyDis.2022;80:174–185.e1.196.Luna-ZaizarH,Virgen-MontelongoM,Cortez-AlvarezCR,etal.Invitro
interferencebyacetaminophen,aspirin,andmetamizoleinserum
measurementsofglucose,urea,andcreatinine.ClinBiochem.2015;48:538–541.197.GreenbergN,RobertsWL,BachmannLM,etal.Specicitycharacteristicsof7commercialcreatininemeasurementproceduresbyenzymaticand
Jaffemethodpri

---

### Chunk 7/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.593

S(i)renin-angiotensin-aldosteronesystem(inhibitor)RBCredbloodcellRCTrandomizedcontrolledtrialRRrelativeriskSCrserumcreatinineSBPsystolicbloodpressureSESsocioeconomicstatusSGLT2isodium-glucosecotransporter-2inhibitor(s)T1DType1diabetesT2DType2diabetesUKUnitedKingdomUSUnitedStatesUSRDSUnitedStatesRenalDataSystem
WHOWorldHealthOrganization
abbreviationsandacronymswww.kidney-international.orgS128KidneyInternational(2024)105(Suppl4S),S117–S314

NoticeSECTIONI:USEOFTHECLINICALPRACTICEGUIDELINEThisClinicalPracticeGuidelinedocumentisbaseduponliteraturesearchesconductedfromJuly2022throughApril2023andupdatedinJuly2023.Itisdesignedtoassistdecision-making.Itisnotintendedtodeneastandardofcareandshouldnotbeinterpretedasprescribinganexclusivecourseofmanagement.Variationsinpracticewillinevitablyandappropriatelyoccur
whencliniciansconsidertheneedsofindividualpatients,availableresources,andlimitationsuniquetoaninstitutionortypeof
practice.Healthcareprovidersusingthestatementsinthisdocument(bothpracti

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.589

romnaturalvariation.Lastly,itshouldbenotedthatrestrictingsaltintake
mayhelpensuremaximaleffectsofRASi.PracticePoint3.6.7:ContinueACEiorARBinpeoplewithCKDevenwhentheeGFRfallsbelow30ml/minper
1.73m2.InarecentSTOP-ACEitrialof411participantswithmeaneGFRof13ml/minper1.73m2,apolicyofdiscontinuingRASiinCKDG4–G5didnotresultinanykidneyorcar-diovascularbenets.507Twoobservationalstudieshavealsofoundthatassociationssuggestingoutcomeswereworse
amongparticipantswhostoppedRASiafterreachingan
www.kidney-international.orgchapter3KidneyInternational(2024)105(Suppl4S),S117–S314S213

eGFR<30ml/minper1.73m2,comparedwiththosewhocontinue.508,509Inaddition,arecentindividualpatientleveldatameta-analysisdemonstratedabenetindelayingKRTinpatientswitheGFR<30ml/minper1.73m2.5103.7Sodium-glucosecotransporter-2inhibitors(SGLT2i)TheWorkGroupconcurswiththeKDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease,whichstated:“Werecommendtreatingpa-tientswithtype2diabetes(T2D),CKD,andaneGFR$20

---

### Chunk 9/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** methods | **Similarity:** 0.589

torytodietaryintervention,orcognitiveimpairment
summaryofrecommendationstatementsandpracticepointswww.kidney-international.orgS168KidneyInternational(2024)105(Suppl4S),S117–S314

Chapter1:EvaluationofCKD1.1DetectionandevaluationofCKDBothdecreasedGFRandincreasedalbuminuriaorothermarkersofkidneydamageareoftensilentandnotapparentto
thepersonatriskofCKDorthehealthcareproviderunless
laboratorytestsareperformed.ThecauseofthedecreasedGFR
orincreasedalbuminuriamayalsonotbeapparent.InthedecadesincethepublicationofthepreviousKDIGOClinicalPracticeGuidelinefortheEvaluationandManagementof
ChronicKidneyDisease,1therehavebeensubstantialadvancesintreatmentforCKDofallcauses(Chapter3),targeted
therapiesforspeciccausesofCKD(e.g.,KDIGO2021ClinicalPracticeGuidelinefortheManagementof
GlomerularDiseases22),aswellasunderstandingofandmethodstodeterminetheetiologyofCKD.Alltogether,theseadvanceshavethepotentialtoslowandpossiblypreventtheprogressionofkidneydisease.Thus,inthissectionofChapter
1,weemphasizetheim

---

### Chunk 10/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.588

orLipidManagementinChronicKidneyDisease.KidneyIntSuppl.2013;3:S1–S305.20.KidneyDisease:ImprovingGlobalOutcomesCKD-MBDWorkGroup.KDIGO2017clinicalpracticeguidelineupdateforthediagnosis,evaluation,prevention,andtreatmentofchronickidneydisease-
mineralandbonedisorder(CKD-MBD).KidneyIntSuppl.2017;7:1–59.21.KidneyDisease:ImprovingGlobalOutcomesBloodPressureWork
Group.KDIGO2021clinicalpracticeguidelineforthemanagementof
bloodpressureinchronickidneydisease.KidneyInt.2021;99(3S):S1–S87.22.KidneyDisease:ImprovingGlobalOutcomesGlomerularDiseasesWork
Group.KDIGO2021clinicalpracticeguidelineforthemanagementof
glomerulardiseases.KidneyInt.2021;100(4S):S1–S276.23.KidneyDisease:ImprovingGlobalOutcomesDiabetesWorkGroup.

---

### Chunk 11/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.587

aprospective,multicentre,randomised,parallelgroup,phase3study.
LancetDiabetesEndocrinol.2022;10:341–350.530.LiuJ,CuiJ,FangX,etal.Efcacyandsafetyofdapagliozininchildrenwithinheritedproteinurickidneydisease:apilotstudy.KidneyIntRep.2022;7:638–641.531.CurrieG,TaylorAH,FujitaT,etal.Effectofmineralocorticoidreceptor
antagonistsonproteinuriaandprogressionofchronickidneydisease:
asystematicreviewandmeta-analysis.BMCNephrol.2016;17:127.532.McDonaghTA,MetraM,AdamoM,etal.2021ESCGuidelinesforthe
diagnosisandtreatmentofacuteandchronicheartfailure:developed
bytheTaskForceforthediagnosisandtreatmentofacuteand
chronicheartfailureoftheEuropeanSocietyofCardiology(ESC).With
thespecialcontributionoftheHeartFailureAssociation(HFA)ofthe
ESC.EurJHeartFail.2022;24:4–131.

---

### Chunk 12/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.585

Figure9|Actionablegenesinkidneydisease.Actionabilityreferstothepotentialforgeneticrestresultstoleadtospecicclinicalactionsfrompreventionortreatmentofacondition,supportedbyrecommendationsbasedonevidence.ADPKD,autosomaldominantpolycystickidneydisease;aHUS,atypicalhemolyticuremicsyndrome,CKD,chronickidneydisease;RAAS,renin-angiotensin-aldosteronesystem,SRNS,
steroid-resistantnephroticsyndrome.ReproducedfromKDIGOConferenceParticipants.Geneticsinchronickidneydisease:conclusionsfroma
KidneyDisease:ImprovingGlobalOutcomes(KDIGO)ControversiesConference.KidneyInt.2022;101:1126–1141.100Copyrightª2022,KidneyDisease:ImprovingGlobalOutcomes(KDIGO).PublishedbyElsevierInc.onbehalfoftheInternationalSocietyofNephrology.Thisisanopen
accessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

### Chunk 13/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.584

national(2024)105(Suppl4S),S117–S314S201

referralwaittimes,particularlyforhigh-riskindividuals.Inotherclinicalsettingswithrelativelyscarceaccessto
nephrologycare,thesethresholdsshouldbeadjustedto
ensurethatwaittimesareacceptableforlocalstandards.421Discussionofriskshouldalsoconsidertheindividual
person,theircomorbidities,andtheirriskofdeathfrom
othercauses.PracticePoint2.2.2:A2-yearkidneyfailureriskof>10%canbeusedtodeterminethetimingofmultidisciplinarycareinadditiontoeGFR-basedcriteriaandotherclinical
considerations.PeoplewithCKDG4–G5aremorelikelytodevelopcon-currentcomplicationsofCKDincludinganemia,hyper-
kalemia,bonemineraldisorders,and/ormetabolicacidosis
andprotein-energywasting.Inaddition,theyremainathigh
riskforadverseeventsincludingAKI,emergencydepartment
visits,andhospitalizations.Assuch,inmanycountriesand
healthcaresettings,thesepeoplemaybeenrolledininter-
disciplinarycareclinicsorreceivecaremanagementresourcestoreducemorbidityandhealthcarecosts,andtoavoidun-planneddialys

---

### Chunk 14/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.584

onsdevelopedforuseinpeoplewithCKDG3–G5,maynotbevalidforuseinthosewithCKDG1–G2.PracticePoint2.2.5:Usedisease-specic,externallyvalidatedpredictionequationsinpeoplewithimmunoglobulinAnephropathy(IgAN)andautosomaldominantpolycystickidneydisease(ADPKD).2.3PredictionofcardiovascularriskinpeoplewithCKDPracticePoint2.3.1:ForcardiovascularriskpredictiontoguidepreventivetherapiesinpeoplewithCKD,useexternallyvalidatedmodelsthatareeitherdevelopedwithinCKDpopulationsorthatincor-porateeGFRandalbuminuria.PracticePoint2.3.2:Formortalityriskpredictiontoguidediscussionsaboutgoalsofcare,useexternallyvalidatedmodelsthatpredictall-causemortalityspecicallydevelopedintheCKDpopulation.Chapter3:DelayingCKDprogressionandmanagingitscomplications3.1CKDtreatmentandriskmodicationPracticePoint3.1.1:TreatpeoplewithCKDwithacomprehensivetreatmentstrategytoreducerisksofprogressionofCKDanditsassociatedcomplications(Figure17).3.2LifestylefactorsPracticePoint3.2.1:EncouragepeoplewithCKDtoundertakephysicalactivitycom

---

### Chunk 15/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** introduction | **Similarity:** 0.584

eascertainmentofchronicity.Thecareof
peoplewithCKDismultifacetedandcomplex.Severalcritical
aspectsofthiscomprehensivecare,suchasbloodpressure
(BP),diabetes,andlipidmanagement,havebeenaddressedin
otherKDIGOguidelines.Thesetopicswerenotreviewedfor
thecurrentguideline,butrecommendationshavebeen
incorporatedwhererelevantandwereferreaderstothosespecicKDIGOguidelinesandtheirupdates.19–23
www.kidney-international.orgintroduction,qualifyingstatements,andkeyconceptsKidneyInternational(2024)105(Suppl4S),S117–S314S135

Thisclinicalpracticeguidelineincludes2differenttypesofstatements:gradedrecommendations,whicharesupportedbysystematicreviews(i.e.,denovoreviewsconductedbythein-dependentERTorexistinghigh-qualityreviewsthathavebeen
systematicallyidentied),andungradedpracticepoints,whichservetodirectclinicalcareoractivitiesforwhichasystematic
reviewwasnotconductedforvariousreasons(e.g.,lackofa
sufcientevidencebaseorrandomizedcontrolledtrials[RCTs]wouldbeimpractical/unethical).Bothrecommenda-
ti

---

### Chunk 16/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.582

TS,LeeT,etal.KDOQIclinicalpracticeguidelineforvascularaccess:2019update.AmJKidneyDis.2020;75(suppl2):S1–S164.424.GramsME,BrunskillNJ,BallewSH,etal.Developmentandvalidationof
predictionmodelsofadversekidneyoutcomesinthepopulationwith
andwithoutdiabetes.DiabetesCare.2022;45:2055–2063.425.ChanL,NadkarniGN,FlemingF,etal.Derivationandvalidationofa
machinelearningriskscoreusingbiomarkerandelectronicpatient
datatopredictprogressionofdiabetickidneydisease.Diabetologia.2021;64:1504–1515.426.Cornec-LeGallE,AudrezetMP,RousseauA,etal.ThePROPKDscore:a
newalgorithmtopredictrenalsurvivalinautosomaldominantpolycystickidneydisease.JAmSocNephrol.2016;27:942–951.427.IrazabalMV,RangelLJ,BergstralhEJ,etal.Imagingclassicationofautosomaldominantpolycystickidneydisease:asimplemodel
forselectingpatientsforclinicaltrials.JAmSocNephrol.2015;26:160–172.428.BarbourSJ,CoppoR,ZhangH,etal.Evaluatinganewinternationalrisk-
predictiontoolinIgAnephropathy.JAMAInternMed.2019;179:942–952.429.BerthouxF,MoheyH,L

---

### Chunk 17/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.582

anddiabetes:anindividual-participantdatameta-analysisinaGlobalConsortium.Hypertension.2021;78:1042–1052.386.PantaloneKM,JiX,KongSX,etal.Unmetneedsandopportunitiesforoptimalmanagementofpatientswithtype2diabetesandchronickidneydisease.JDiabetesComplications.2023;37:108418.387.KimHS,NgDK,MathesonMB,etal.AssociationofpubertywithchangesinGFRinchildrenwithCKD.AmJKidneyDis.2022;79:131–134.388.GianluigiA,SaraT,ValeriaD,etal.PubertyisassociatedwithincreaseddeteriorationofrenalfunctioninpatientswithCKD:datafromtheItalKidProject.ArchDisChild.2012;97:885–888.389.OshimaM,JardineMJ,AgarwalR,etal.InsightsfromCREDENCEtrialindicateanacutedropinestimatedglomerularltrationrateduringtreatmentwithcanagliozinwithimplicationsforclinicalpractice.KidneyInt.2021;99:999–1009.390.KrausBJ,WeirMR,BakrisGL,etal.Characterizationandimplicationsof
theinitialestimatedglomerularltrationrate’dip’uponsodium-glucosecotransporter-2inhibitionwithempagliozinintheEMPA-REGOUTCOMEtrial.KidneyInt.2021;99:750–762.

---

### Chunk 18/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** methods | **Similarity:** 0.582

024)105(Suppl4S),S117–S314

intermediateCKDprogressionoutcome,3recentpublica-tionspresentmodelsforpeoplewithorwithoutdiabetes,
usingbothregressionandmachinelearning–basedmethods,withorwithoutbiomarkers(Table20).8,424,425Giventhepotentialutilityofthesenewmodelstoidentifyhigh-risk
peopleforearlyintervention,theyshouldbeusedtopredict
diseaseprogressioninpeoplewithCKDG1–G2andmaysupplementestablishedriskequationsamongpeoplewithCKDG3.PeoplewithCKDidentiedasintermediaterisk(e.g.,>1%peryear)withthesetoolsmaybenetfromtheearlierinitiationoftherapyandcloserfollow-up,andthoseidentiedashighrisk(e.g.,>5%peryear)mayhavethelargestbenetfrommultidrugtherapytoslowprogression.PracticePoint2.2.5:Usedisease-specic,externallyvali-datedpredictionequationsinpeoplewithimmunoglobulinAnephropathy(IgAN)andautosomaldominantpolycystickidneydisease(ADPKD).RiskpredictionmodelsforspecicetiologiesofCKDhavealsobeendeveloped,areexternallyvalidated,andusedin
healthcaresettingstoguideclinicalcare.Forautosomaldom

---

### Chunk 19/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** methods | **Similarity:** 0.581

ey-international.orgS148KidneyInternational(2024)105(Suppl4S),S117–S314

SummaryofrecommendationstatementsandpracticepointsChapter1:EvaluationofCKD1.1DetectionandevaluationofCKD1.1.1DetectionofCKDPracticePoint1.1.1.1:Testpeopleatriskforandwithchronickidneydisease(CKD)usingbothurinealbuminmea-surementandassessmentofglomerularltrationrate(GFR).PracticePoint1.1.1.2:Followingincidentaldetectionofelevatedurinaryalbumin-to-creatinineratio(ACR),hematuria,orlowestimatedGFR(eGFR),repeatteststoconrmpresenceofCKD.1.1.2MethodsforstagingofCKDRecommendation1.1.2.1:InadultsatriskforCKD,werecommendusingcreatinine-basedestimatedglomer-ularltrationrate(eGFRcr).IfcystatinCisavailable,theGFRcategoryshouldbeestimatedfromthecombinationofcreatinineandcystatinC(creatinineandcystatinC–basedestimatedglomerularltrationrate[eGFRcr-cys])(1B).1.1.3EvaluationofchronicityPracticePoint1.1.3.1:Proofofchronicity(durationofaminimumof3months)canbeestablishedby:(i)reviewofpastmeasurements/estimationsofGFR;(ii)revie

---

### Chunk 20/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.580

.Diagnosticaccuracyofpoint-of-caretestsfordetectingalbuminuria:a
systematicreviewandmeta-analysis.AnnIntMed.2014;160:550–557.318SoFtablesSupplementaryTableS5SearchdateJuly2022
Citationsscreened/includedstudies2184/65
SupplementaryFigureS5Chapter2RiskassessmentinpeoplewithCKDClinicalquestionArekidneyfailurepredictionequationsgoodpredictorsofprogression,kidneyfailure,orend-stagerenaldisease?PopulationAdults,children,andyoungpeoplewithCKDG1-G5PredictorKidneyfailureriskequations(e.g.,Tangriequation[KidneyFailureRiskEquation])OutcomesPrognosticperformance:Calibration(goodnessofmeasures,e.g.,R2,Brierscore,andHosmer-Lemeshowtest)Discrimination(e.g.,sensitivity/specicity;areaunderthecurve[AUC]fromreceiveroperatingcharacteristic[ROC]andareaunderthereceiveroperatingcharacteristiccurve[AUROC];C-statistic)StudydesignSystematicreview
ExistingsystematicreviewNationalInstituteforHealthandCareExcellence.Evidencereviewforthebestcombinationofmeasurestoidentifyincreasedriskofprogressioninadults,childr

---

### Chunk 21/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.579

KidneyInt.2022;102(5S):S1–S127.24.GlobalBurdenofDisease2019:GBDcauseandrisksummarieschronic
kidneydisease.Lancet.2020;396:S152–S153.25.GBDChronicKidneyDiseaseCollaboration.Global,regional,andnationalburdenofchronickidneydisease,1990-2017:asystematic
analysisfortheGlobalBurdenofDiseaseStudy2017.Lancet.2020;395:709–733.26.LevinA,OkpechiIG,CaskeyFJ,etal.Perspectivesonearlydetectionof
chronickidneydisease:thefacts,thequestions,andaproposed
frameworkfor2023andbeyond.KidneyInt.2023;103:1004–1008.27.CusickMM,TisdaleRL,ChertowGM,etal.Population-widescreeningfor
chronickidneydisease:acost-effectivenessanalysis.AnnInternMed.2023;176:788–797.28.LameireNH,LevinA,KellumJA,etal.Harmonizingacuteandchronic
kidneydiseasedenitionandclassication:reportofaKidneyDisease:ImprovingGlobalOutcomes(KDIGO)ConsensusConference.KidneyInt.2021;100:516–526.29.deBoerIH,KhuntiK,SaduskyT,etal.Diabetesmanagementinchronic
kidneydisease:aconsensusreportbytheAmericanDiabetes
Association(ADA)andKidneyDisease:Im

---

### Chunk 22/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.578

ropriatetreatment.KeyinformationBalanceofbenetsandharms.Thebenetsofkidneybi-opsyintermsofdiagnosis,prognosis,andplanningappro-
priatetreatmentforboththepersonwithCKDandhealthcare
PhysicalexamNephrotoxicmedicationsSymptoms and signsof urinary tractabnormalitiesSymptoms and signsof systemic diseasesLaboratory tests, imaging, and tissue sample, such as:• Urinalysis and urine sediment• Urine albumin-to-creatinine ratio• Serologic tests
• Ultrasound• Kidney biopsy• Genetic testingMedicalhistorySocial andenvironmentalhistoryObtain careful family historyfor possible genetic causes,including family pedigree for CKD
Figure8|Evaluationofcauseofchronickidneydisease(CKD).

---

### Chunk 23/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.575

tagechronickidneydisease:comparativeresultsfromanopen-label,phase3study.NephrolDialTransplant.2021;36:137–150.585.ThinkKidneys,theRenalAssociationandtheBritishSocietyforHeartFailure.ChangesinkidneyfunctionandserumpotassiumduringACE/
ARB/diuretictreatmentinprimarycare.Apositionstatement;2017.

---

### Chunk 24/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.573

tsintheprocessesofdrugstewardshipinpeople
withCKD.Itisbeyondthescopeofthisguidelinetolistall
themedicationsthatmayhavealteredrisks/benetsinpeoplewithCKD.Suchinformationiswidelyavailablein
documentsthatmayexistatlocal,regional,ornationalbodies(e.g.,BritishNationalFormulary:www.bnf.org)andintextbooksofpharmacology.However,wedescribecaseexamplestohighlightthekeyclassesofcommonlypre-
scribedmedicationsinpeoplewithCKD.Thisguidanceis
basedonknowledgeofpharmacologythathasuniversal
relevance.Inmanycases,knowledgeofalteredrisks/benetsofmedicationscomes,however,fromobservationalstudies
andcasereportsfromroutinecare.4.1MedicationchoicesandmonitoringforsafetyAbnormalkidneyfunctionresultsinalterationinpharma-cokineticsandpharmacodynamics,andforpeoplewithCKD,astheGFRworsens,sodoestheprevalenceofpolypharmacy
andcomorbidities.725PeoplewithCKDareatincreasedriskofmedicationerrorsandinappropriateprescribing(noted
tobeupto37%inambulatoryoutpatientstudiesandup
to43%inlong-termcarestudies726,727).Thus,imp

---

### Chunk 25/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.572

arltrationrate[eGFRcr-cys])(1B).1.1.3EvaluationofchronicityPracticePoint1.1.3.1:Proofofchronicity(durationofaminimumof3months)canbeestablishedby:(i)reviewofpastmeasurements/estimationsofGFR;(ii)reviewofpastmeasurementsofalbuminuriaorproteinuriaandurinemicroscopicexaminations;(iii)imagingndingssuchasreducedkidneysizeandreductionincorticalthickness;(iv)kidneypathologicalndingssuchasbrosisandatrophy;(v)medicalhistory,especiallyconditionsknowntocauseorcontributetoCKD;(vi)repeatmeasurementswithinandbeyondthe3-monthpoint.PracticePoint1.1.3.2:DonotassumechronicitybaseduponasingleabnormallevelforeGFRandACR,asthendingcouldbetheresultofarecentacutekidneyinjury(AKI)eventoracutekidneydisease(AKD).PracticePoint1.1.3.3:ConsiderinitiationoftreatmentsforCKDatrstpresentationofdecreasedGFRorelevatedACRifCKDisdeemedlikelyduetopresenceofotherclinicalindicators.1.1.4Evaluationofcause
PracticePoint1.1.4.1:EstablishthecauseofCKDusingclinicalcontext,personalandfamilyhistory,socialandenvi-ronmentalfactor

---

### Chunk 26/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.571

lurinarytractdiseaseRecurrentkidneycalculiMultisystemdiseases/chronicinammatoryconditionsSystemiclupuserythematosus
Vasculitis
HIVIatrogenic(relatedtodrugtreatmentsandprocedures)Drug-inducednephrotoxicityandradiationnephritisFamilyhistoryorknowngeneticvariantassociatedwithCKDKidneyfailure,regardlessofidentiedcauseKidneydiseaserecognizedtobeassociatedwithgeneticabnormality(e.g.,PKD,APOL1-mediatedkidneydisease,andAlportsyndrome)GestationalconditionsPretermbirthSmallgestationalsizePre-eclampsia/eclampsiaOccupationalexposuresthatpromoteCKDriskCadmium,lead,andmercuryexposurePolycyclichydrocarbonsPesticidesAKD,acutekidneydisease;AKI,acutekidneyinjury;APOL1,apolipoproteinL1;CKD,chronickidneydisease;CKDu,chronickidneydiseaseofundeterminedorigin;PKD,polycystickidneydisease.

---

### Chunk 27/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.571

onrate(GFR)andalbuminuriainpeoplewithchronickidneydisease(CKD)S199Figure14.(a)Predictedriskofkidneyfailureand(b)‡40%declineinestimatedglomerularltrationrate(eGFR)bychronickidneydisease(CKD)eGFR(G1–G5)andalbumin-to-creatinineratio(ACR)(A1–A3)categoriesinOptumLabsDataWarehouseS201Figure15.Transitionfromanestimatedglomerularltrationrate(eGFR)-basedtoarisk-basedapproachtochronickidneydiseasecareS202Figure16.Comparisonofriskofchronickidneydisease(CKD)progression(5-yearprobabilityofestimatedglomerularltrationrate[eGFR]<60ml/minper1.73m2)versuskidneyfailureinadultswithCKDG1–G2calculatedfromtheriskequationavailableathttps://www.ckdpc.org/risk-models.htmlS205Figure17.Chronickidneydisease(CKD)treatmentandriskmodicationS206Figure18.Holisticapproachtochronickidneydisease(CKD)treatmentandriskmodicationS208Figure19.Proteinguidelineforadultswithchronickidneydiseasenottreatedwithdialysis
contentswww.kidney-international.orgS120KidneyInternational(2024)105(Suppl4S),S117–S314

S209Figure2

---

### Chunk 28/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.569

specickidneyfunctionofglomerularltration.Usethemoregeneralterm“kidneyfunction(s)”whendealingwiththetotalityoffunctionsofthekidney.
PhysicalexamNephrotoxicmedicationsSymptoms and signsof urinary tractabnormalitiesSymptoms and signsof systemic diseasesLaboratory tests, imaging, and tissue sample, such as:• Urinalysis and urine sediment• Urine albumin-to-creatinine ratio• Serologic tests
• Ultrasound• Kidney biopsy• Genetic testingMedicalhistorySocial andenvironmentalhistoryObtain careful family historyfor possible genetic causes,including family pedigree for CKD
Figure8|Evaluationofcauseofchronickidneydisease(CKD).

---

### Chunk 29/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.569

eknowledgegainedmoreeffec-
tively.793–797PracticalimplementationtipsinvolveprintingouttheresultsofthemostrecenteGFRestimationforthe
patienttobringalonginfuturehealthcareconsultationsand/
orwritedownalistofongoingmedicationstoalertotherhealthcareprovidersofmedicationrisksandbenets.AdiagnosisofCKDshouldalwaysbereectedinmedicalrecords,asthiswillalertphysiciansontheneedtoconsideradjustingoravoidingcertainmedicationsorprocedures.Under-recognitionofCKDdiagnosesinmedicalrecordsis
associatedwithmedicationerrors,includingpotentially
inappropriateprescriptionofnephrotoxicmedications.729PracticePoint4.3.1.2:Establishcollaborativerelationships
withotherhealthcareprovidersandpharmacistsand/or
usetoolstoensureandimprovedrugstewardshipinpeople
withCKDtoenhancemanagementoftheircomplex
medicationregimens.Clinicalpharmacistsarehighlyqualiedexpertsinmedi-cinesand,aspartofthemultidisciplinaryteam,canplaya
pivotalroleinimprovingthequalityofcareandensuringpatientsafetyinarangeofways.Thisincludescarryin

---

### Chunk 30/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.569

adultswithadvancedchronickidneydisease:resultsfromthe
EQUALstudy.JRenNutr.2018;28:165–174.876.LimSL,LinXH,DanielsL.Seven-pointsubjectiveglobalassessmentis
moretimesensitivethanconventionalsubjectiveglobalassessmentin
detectingnutritionchanges.JPENJParenterEnteralNutr.2016;40:966–972.877.GraterolTorresF,MolinaM,Soler-MajoralJ,etal.Evolvingconceptson
inammatorybiomarkersandmalnutritioninchronickidneydisease.Nutrients.2022;14:4297.878.PawlaczykW,RogowskiL,KowalskaJ,etal.Assessmentofthenutritional
statusandqualityoflifeinchronickidneydiseaseandkidneytransplant
patients:acomparativeanalysis.Nutrients.2022;14:4814.879.Epping-JordanJE,PruittSD,BengoaR,etal.Improvingthequalityof
healthcareforchronicconditions.QualSafHealthCare.2004;13:299–305.880.NicollR,RobertsonL,GemmellE,etal.Modelsofcareforchronickidneydisease:asystematicreview.Nephrology(Carlton).2018;23:389–396.881.CollisterD,PyneL,CunninghamJ,etal.Multidisciplinarychronickidneydiseaseclinicpractices:ascopingreview.CanJKidneyHea

---

